125342-94-1

Upstream product

• 2923-18-4 sodium 2,2,2-trifluoroacetate 
• 79-37-8 oxalyl dichloride 
• 13515-93-0 N-methylglycine methyl ester hydrochloride 
• 134057-89-9 2-Benzyloxy-6-methoxy-naphthalene-1-carboxylic acid 
• 125342-95-2 6-methoxy-2-(phenylmethoxy)-1-naphthalenecarboxaldehyde 
• 55218-08-1 2,6-dimethoxy-1-naphthalenecarbaldehyde 
• 50493-59-9 2-hydroxy-6-methoxynaphthalene-1-carbaldehyde 

Downstream Products

• 134057-63-9 [(2-Benzyloxy-6-methoxy-5-trifluoromethyl-naphthalene-1-carbonyl)-methyl-amino]-acetic acid 
• 124323-67-7 [(2-Benzyloxy-6-methoxy-5-trifluoromethyl-naphthalene-1-carbothioyl)-methyl-amino]-acetic acid 

Relevant academic research and scientific papers

Syntheses of tolrestat analogues containing additional substituents in the ring and their evaluation as aldose reductase inhibitors. Identification of potent, orally active 2-fluoro derivatives

A series of aldose reductase inhibitors were prepared which were analogues of the potent, orally active inhibitor tolrestat (1). These compounds (5, 7, 9, and 10) have an extra substituent on one of the unoccupied positions on the naphthalene ring of 1. P

Production of N-((2-alkoxy-6-methoxy-5-(trifluoromethyl)-1-naphthalenyl)carbonyl)-N-methylglycine esters

Process for the production of N-[[2-alkoxy-6-methoxy-5-(trifluoromethyl)-1-naphthalenyl]carbonyl]-N-methylglycine esters and intermediates for their production. Said esters are themselves intermediates for the manufacture of compounds which inhibit aldose